Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted treatment option after the FDA cleared capivasertib, sold as Truqap, for use alongside abiraterone and prednisone. The approval, granted on June 12, 2026, applies to patients whose tumors show loss of the PTEN protein, a genetic alteration that drives aggressive disease through the PI3K-AKT signaling pathway. The decision also triggered a simultaneous green light for the first companion diagnostic designed to detect PTEN protein loss in prostate tissue, linking a lab test directly to a drug for the first time in this cancer type.
Why PTEN-deficient prostate cancer needed a new drug
Standard androgen-targeting therapies have long formed the backbone of treatment for metastatic hormone-sensitive prostate cancer, but a subset of patients with PTEN-deficient tumors tend to progress faster. PTEN loss activates an alternative growth pathway that can bypass hormone blockade, leaving these patients with fewer effective options. The FDA described capivasertib’s role in this setting in its announcement of the drug’s use for PTEN-deficient disease, underscoring a shift toward matching drugs to molecular tumor profiles rather than treating all advanced prostate cancers the same way.
The practical question is whether PTEN testing will quickly become routine in clinical workups for newly diagnosed metastatic disease. A reasonable expectation is that payer requirements, not survival data alone, will push adoption. Because the drug label restricts use to patients with confirmed PTEN protein loss, insurers and pharmacy benefit managers will almost certainly require documented test results before authorizing coverage. That dynamic could make PTEN immunohistochemistry a standard step in the diagnostic process within the next year or so, even before long-term survival results from the supporting trial are mature.
CAPItello-281 trial data and the ODAC review
The approval rests on results from the CAPItello-281 trial, a randomized study that enrolled patients with metastatic hormone-sensitive prostate cancer and centralized immunohistochemistry-confirmed PTEN deficiency. The trial measured radiographic progression-free survival as its primary endpoint, comparing capivasertib plus abiraterone and prednisone against placebo plus abiraterone and prednisone. Secondary endpoints included overall survival, objective response in patients with measurable disease, and safety outcomes.
The FDA’s Oncologic Drugs Advisory Committee reviewed the data at an April 30, 2026, meeting under NDA 218197 s-4, where agency staff presented an in-depth analysis of radiographic progression-free survival, hazard ratios, and subgroup outcomes in a publicly posted briefing document. That analysis highlighted a clear separation in progression curves between the capivasertib arm and control, with fewer radiographic events and delayed time to progression in patients receiving the triplet regimen. The committee discussion focused on whether the magnitude of benefit justified the added toxicity and complexity of therapy at such an early stage of metastatic disease.
Toxicity drew close scrutiny. Investigators reported higher rates of diarrhea, rash, and infections in the capivasertib arm, including a subset of patients with grade 3 or 4 events that required dose interruptions, reductions, or permanent discontinuation. Hyperglycemia, a known class effect of AKT inhibition, also emerged as a clinically relevant concern, particularly in patients with baseline metabolic risk factors. ODAC members emphasized that the benefit–risk balance would depend heavily on careful patient selection and proactive management of side effects.
The updated prescribing information, posted on DailyMed on June 12, 2026, details the recommended dosing schedule for capivasertib in combination with abiraterone and prednisone, along with contraindications and warnings. The label includes boxed and bolded language on hyperglycemia, diarrhea, rash, and infections, as well as guidance on monitoring blood glucose, managing severe gastrointestinal events, and adjusting doses when toxicities arise. Drug–drug interaction sections outline how strong CYP3A modulators and other concomitant medications can affect capivasertib exposure, helping clinicians navigate polypharmacy in an older patient population.
Crucially, the indication language specifies that capivasertib is approved only for patients whose PTEN deficiency has been confirmed by an FDA-approved test. That requirement operationalizes the biomarker-driven nature of this therapy and directly links prescribing decisions to pathology results. In practice, oncologists will need to coordinate closely with pathologists to ensure that adequate tumor tissue is available and that testing is ordered early enough to inform first-line treatment planning.
On the diagnostic side, Roche Tissue Diagnostics received premarket approval for the VENTANA PTEN (SP218) RxDx Assay under PMA P250031. The immunohistochemistry test is designed for use on formalin-fixed, paraffin-embedded prostate adenocarcinoma tissue, providing a binary readout of PTEN protein status that can be integrated into routine pathology workflows. Roche characterized the assay as the first companion diagnostic cleared to assess PTEN protein in people living with prostate cancer, creating the testing infrastructure needed to identify eligible patients and aligning laboratory practice with the new therapeutic indication.
Gaps in the evidence and what to watch next
The most significant gap in the current data is the absence of mature overall survival results from CAPItello-281. Radiographic progression-free survival, while a meaningful measure of disease control, does not answer the question patients and oncologists care about most: whether the drug extends life. As the trial continues to follow participants, subsequent analyses will need to show that early gains in radiographic endpoints translate into a survival advantage, particularly given the availability of multiple life-prolonging therapies later in the disease course.
Patient-reported outcomes represent another area of uncertainty. The trial protocol incorporated validated questionnaires to assess health-related quality of life, fatigue, and treatment burden, but detailed results from those instruments have not yet been fully disseminated. Without those data, it is difficult to quantify how much the added toxicities of capivasertib affect day-to-day functioning in a population that may remain on therapy for extended periods. Clinicians will have to rely on individual patient preferences and tolerance for side effects when deciding whether to add capivasertib to a regimen that already includes androgen pathway suppression.
Real-world access presents its own set of challenges. The triplet regimen of capivasertib, abiraterone, and prednisone adds cost and complexity, both for patients and for health systems. Pricing and insurance coverage terms for capivasertib in this new indication have not been spelled out in the regulatory documents, leaving uncertainty about copay levels, prior authorization hurdles, and potential step-therapy requirements. Because the indication is restricted to PTEN-deficient disease, payers are likely to insist on documented use of the companion diagnostic, which could delay treatment initiation if pathology workflows are not optimized.
Community oncology practices, which treat the majority of men with metastatic prostate cancer in many regions, will bear much of the implementation burden. These practices must ensure reliable access to the VENTANA PTEN assay, either by partnering with reference laboratories or by validating the test in-house if they have the appropriate platforms. They will also need protocols for monitoring glucose, skin toxicity, and gastrointestinal symptoms, as well as staff training to recognize early signs of serious adverse reactions. Smaller centers with limited supportive resources may be more cautious in adopting the regimen until they are confident they can manage its complexities.
Equity concerns may surface as PTEN testing and capivasertib use expand. Patients treated at well-resourced academic centers are more likely to undergo comprehensive molecular profiling and to have rapid turnaround times for biomarker results, while those in rural or underfunded settings may face delays or lack of access to the companion diagnostic. If reimbursement for the assay is inconsistent, some institutions may be reluctant to absorb the cost, potentially widening disparities in who is offered the new therapy. Policymakers and professional societies will need to monitor uptake patterns and consider guidance to promote equitable implementation.
For now, the approval of capivasertib paired with a PTEN-targeted companion diagnostic marks a notable step toward precision oncology in metastatic prostate cancer. As longer-term survival and quality-of-life data emerge, clinicians will gain a clearer view of where this regimen fits among existing options and which patients stand to benefit most. In the interim, the decision underscores an increasingly common theme in oncology: effective use of new targeted agents depends as much on diagnostic infrastructure and system-level readiness as on the pharmacology of the drug itself.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
